Dr. Neri is a Clinical Associate Professor of Medicine, attending physician in the Hematology division at University of Calgary and member of the Arnie Charbonneau Cancer Institute. She received her medical degree at Magna Græcia University, Catanzaro, Italy in 2000. She completed her specialty in Medical Oncology at Magna Græcia University, Catanzaro, Italy in 2005 and received a PhD in Molecular Oncology and Experimental Immunology in 2011. From 2003-2006 Dr. Neri was a Research Associate at Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA under the mentorship of Dr. Kenneth Anderson and Dr. Nikhil Munshi. The main focus of her research is to investigate the genome signature associated with myeloma resistance to anti-MM agents and to identify druggable therapeutic targets in myeloma.
Dr. Neri is well published in the field and some of her research work included the development of the scid-hu myeloma model and the pre-clinical investigation of several classes of drugs in this disease. Several of these pre-clinically validated targets are currently in early phase I clinical studies (BAFF inhibitors, HDAC inhibitors, ITGB-7 and PARP inhibitors). She has received national and international grants from several agencies including Myeloma Canada, Leukemia and Lymphoma Society, The International Multiple Myeloma Research Foundation and Canadian Institute of Health Research (CIHR). She presented her research at numerous national and international meetings, and have chaired and participated in numerous international forums including the American Society of Hematology and the International Myeloma Workshop. Dr. Neri is currently a member of the American Society of Hematology and the scientific board of Myeloma Canada, very active both in preclinical and clinical trial research in Myeloma.